Bipolar Disorder (Mania)

Subscribe to Selected New Research on Bipolar Disorder

5335 relevant articles (729 outcomes, 1147 trials/studies) found for this Disease

Description: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

Also Known As:

Mania; Manias; Manic Depressive Psychosis; Depression, Bipolar; Bipolar Disorders; Manic State; Manic Disorders; Psychoses, Manic-Depressive; Bipolar Affective Psychosis; Bipolar Depression; Disorder, Bipolar; Disorder, Manic; Manic States; Manic-Depressive Psychoses; Psychoses, Bipolar Affective; Psychoses, Manic Depressive; Psychosis, Bipolar Affective; Psychosis, Manic Depressive; State, Manic; States, Manic; Affective Psychosis, Bipolar; Manic Disorder; Manic-Depressive Psychosis; Psychosis, Manic-Depressive

Relationship Network

Disease Context: Research Results

Mental Disorders: 1709

Mood Disorders: 4144

Psychotic Affective Disorders: 138

Bipolar Disorder: 5335

Cyclothymic Disorder: 10

Related Diseases

1.	Bipolar Disorder (Mania)
2.	Schizophrenia (Dementia Praecox)
3.	Depressive Disorder (Melancholia)
4.	Psychotic Disorders (Schizoaffective Disorder)
5.	Mood Disorders (Mood Disorder)

Experts

1.	Keck, Paul E: 34 articles (11/2007 - 01/2002)
2.	Calabrese, Joseph R: 30 articles (09/2008 - 01/2002)
3.	Vieta, Eduard: 29 articles (10/2008 - 10/2002)
4.	Ketter, Terence A: 27 articles (05/2008 - 05/2002)
5.	Suppes, Trisha: 27 articles (01/2008 - 01/2002)
6.	Tohen, Mauricio: 25 articles (09/2008 - 01/2002)
7.	Bowden, Charles L: 23 articles (05/2008 - 01/2002)
8.	Yatham, Lakshmi N: 22 articles (03/2008 - 01/2002)
9.	McElroy, Susan L: 21 articles (11/2007 - 01/2002)
10.	Kato, Tadafumi: 19 articles (07/2008 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Bipolar Disorder:

1.	LithiumIBA 02/16/2006 - "The mood stabilizing drug lithium is a highly effective treatment for bipolar disorder" 01/01/2005 - "Lithium is best described as the bench mark treatment for bipolar disorder, rather than the gold standard, because only a minority of patients show major clinical benefit" 08/01/2002 - "Lithium is also highly effective in the treatment of bipolar disorder, however, the mechanism of lithium action in the treatment of this psychiatric disorder is still unknown" 01/01/2000 - "RESULTS: Lithium is currently the gold standard and most appropriate initial treatment for the depressive phase of bipolar disorder" 09/01/1998 - "The data analyzed give strong support for lithium's being most effective in bipolar disorder, with minimal or no therapeutic effects in other neuropsychiatric disorders" Order ALL the reference details at left...
2.	Valproic Acid (Valproate, Semisodium)FDA LinkGeneric 01/01/2007 - "Guidelines for the treatment of type I bipolar disorder in children and adolescents, with or without psychotic features, recommend valproate, alone or in combination with an atypical antipsychotic, as a first-line treatment option; however, most randomised and open-label studies investigating valproate in paediatric populations have only evaluated a small number of participants" 06/01/2003 - "Valproate appears at best modestly effective for bipolar depression" 10/01/2000 - "BACKGROUND: Sodium valproate is a highly effective treatment for bipolar disorder, but its mechanism of action remains poorly understood" 10/01/2000 - "Divalproex has proven efficacy in the treatment of bipolar disorder" 01/01/2000 - "Valproate has proven effective in treating bipolar disorder" Order ALL the reference details at left...
3.	Antipsychotic Agents (Antipsychotics)IBA 01/01/2005 - "The atypical antipsychotics, with their proven efficacy against manic symptoms, are emerging as candidates for use against the depressive phase of bipolar disorder" 01/01/2005 - "Atypical antipsychotics appear to have broadly similar efficacy against manic symptoms of bipolar disorder, but there are important differences in their tolerability profiles, which are likely to be of particular relevance during long-term treatment" 01/01/2007 - "With mania or mixed presentation atypical antipsychotics produced significantly better rates of response and symptomatic remission than placebo, with NNTs of about 5 up to six weeks, and 4 at 6-12 weeks, but more adverse event withdrawals (NNH of about 22) in studies of 6-12 weeks" 01/01/2005 - "Subgroup analyses from trials treating manic phase bipolar disorder, and an open-label study of rapid cycling, have suggested that atypical antipsychotics may be useful for the treatment of mixed states and rapid cycling" 02/01/2008 - "All atypical antipsychotics caused a significantly greater incidence of somnolence than placebo in mania and depression, with NNTHs from 5 to 8 for mania and 2 to 6 for depression" Order ALL the reference details at left...
4.	lamotrigine (Lamictal)FDA LinkGeneric 10/01/2002 - "Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder" 05/01/2006 - "RESULTS: The base-case model for patients with a recent manic episode indicated that lamotrigine is the most effective treatment for avoiding both acute depression episodes and all types of acute episodes (depression and mania)" 01/01/2004 - "Lamotrigine is the most widely studied and is effective in treating and preventing bipolar depression, and it is the only anticonvulsant approved by the U.S" 05/01/2000 - "Lamotrigine has the most evidence in favor of its efficacy, with two double-blind studies in which it was more efficacious than placebo in the treatment of bipolar depression" 04/01/2003 - "BACKGROUND: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials" Order ALL the reference details at left...
5.	olanzapine (Zyprexa)FDA Link 05/01/2006 - "Olanzapine is most effective for avoiding acute mania episodes" 11/01/2004 - "Olanzapine monotherapy significantly improved depressive symptoms compared with placebo in patients with bipolar disorder in an 8-week randomized, controlled clinical study, but the magnitude of the clinical effect was small" 10/01/2007 - "RESULTS: The mean baseline-to-endpoint change in the Young Mania Rating Scale total score was significantly greater for patients receiving olanzapine relative to patients receiving placebo, and a greater proportion of olanzapine-treated patients met response and remission criteria (44.8% versus 18.5% and 35.2% versus 11.1%, respectively)" 09/01/2004 - "The olanzapine treatment group had significantly greater mean improvement of mania ratings and a significantly greater proportion of patients achieving protocol-defined remission" 09/01/2004 - "RESULTS: Olanzapine-treated patients experienced modest but significant improvement in PANSS-Cognitive score (olanzapine: -4.25 n = 124; placebo: -1.69 n = 120, p < 01), regardless of age, gender, mania subtype (pure, mixed), course (rapid or non-rapid cycling), or the presence or absence of psychotic features" Order ALL the reference details at left...
6.	Carbamazepine (Tegretol)FDA LinkGeneric 03/01/2005 - "CONCLUSION: Extended-release carbamazepine monotherapy had significantly greater efficacy compared with placebo in the treatment of acute mania in this large, randomized, double-blind, placebo-controlled trial." 01/01/2005 - "At study end, reductions from baseline in Young Mania Rating Scale scores were significantly greater with carbamazepine than with placebo (primary endpoint)" 04/01/1993 - "Although controlled trials have demonstrated the efficacy of carbamazepine for the treatment of rapid cycling bipolar disorder, the response to carbamazepine frequently deteriorates" 01/01/2006 - "OBJECTIVES: Recently, two large, 3-week, randomised, double-blind, placebo-controlled trials using nearly identical protocols demonstrated that monotherapy with carbamazepine extended-release capsules (CBZ-ERC) was effective for the treatment of acute mania in patients with bipolar I disorder" 09/01/2005 - "Using nearly identical protocols, these trials demonstrated that monotherapy with carbamazepine extended-release capsules was effective for the treatment of acute mania in patients with bipolar I disorder" Order ALL the reference details at left...
7.	Risperidone (Risperdal Consta)FDA Link 02/01/2008 - "Although both hyperactive/impulsive (-7.5 +/- 5.5.6, p < 0.05) and inattentive (-6.8 +/- 5.0, p < 0.05) ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6) showed a 30% reduction in ADHD rating scale scores and had a CGI-I </= 2. CONCLUSIONS: These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder." 01/01/2005 - "At week 3, mean Young Mania Rating Scale (YMRS) score reductions from baseline were significantly greater in patients receiving risperidone than placebo (p<0.001)" 06/01/2004 - "Improvement in mean Young Mania Rating Scale total score (adjusted for covariates) was significantly greater in the risperidone than in the placebo group at endpoint (mean change=-10.6 [SD=9.5] versus -4.8 [SD=9.5], respectively), with significant between-group differences seen as early as 3 days after start of treatment (change with risperidone: mean=-6.8 [SD=5.8]; change with placebo: mean=-4.0 [SD=5.8]) and continuing throughout all time points" 05/01/2004 - "At double-blind endpoint, mean reductions in Young Mania Rating Scale (YMRS) scores were significantly greater in patients receiving risperidone plus mood stabilizer than in those receiving placebo plus mood stabilizer (-14.3 vs. -8.2, p <.001)" 02/01/2003 - "RESULTS: Young Mania Rating Scale (YMRS) scores improved rapidly with significantly greater reductions at week 1 in the risperidone group compared with the placebo group" Order ALL the reference details at left...
8.	quetiapine (Seroquel)FDA Link 01/01/2007 - "RESULTS: Quetiapine as monotherapy, or in combination with Li or DVP, was a highly effective treatment for acute mania, as shown by overall change scores in the total YMRS" 01/01/2007 - "CONCLUSIONS: Quetiapine was associated with significantly higher response and remission/euthymia rates compared with placebo with most criteria used, in patients with acute mania at the end of both 3 and 12 weeks." 12/01/2008 - "CONCLUSIONS: Quetiapine monotherapy is effective in improving impairment in important aspects of life that accompany improvements in depressive symptoms in patients with acute bipolar depression." 01/01/2007 - "CONCLUSIONS: At Days 21 and 42, quetiapine combined with Li/DVP compared to Li/DVP monotherapy yielded significant, sustained improvements in the rate of clinical remission/euthymia in patients with bipolar mania" 07/01/2006 - "Safety and efficacy of rapid dose administration of quetiapine in bipolar mania." Order ALL the reference details at left...
9.	Antidepressive Agents (Antidepressants)IBA 01/01/2008 - "Most of the standard randomized controlled trials report the efficacy of antidepressants in the acute phase of BPD, but the data also indicate higher switch rates to mania and acceleration of mood cycle with their use" 10/01/2001 - "RESULTS: Thirty-five (37%) of the 95 acute treatment phases were associated with a much or very much improved rating in depression on the CGI-BP. Thirteen (14%) of these 95 acute trials of antidepressants as adjuncts to mood stabilizers were associated with switches, seven into hypomania and six into mania" 02/01/1999 - "Currently available antidepressants may increase the risk of mania and rapid cycling, and mood stabilizers appear to be less effective in treating depression than mania" 03/01/1992 - "Antidepressant drugs are effective in the acute treatment and prevention of depression only, and can even precipitate hypomanic or manic "switches," or "rapid cycling" between mania and depression" 03/01/2007 - "Although more work is needed to establish the safety and efficacy of second-generation antidepressants in treating bipolar depression, the evidence from this study supports a favorable risk-benefit profile." Order ALL the reference details at left...
10.	Anticonvulsants (Antiepileptic Drugs)IBA 01/01/2005 - "Anticonvulsants and other mood stabilizers may be especially helpful in treating bipolar disorder with significant comorbidity." 01/01/2006 - "Other new antiepileptic drugs may also be effective in bipolar disorder but more solid evidence of their efficacy is needed." 01/01/2006 - "Data on the efficacy of old and new antiepileptic drugs in bipolar disorder obtained in controlled clinical trials are reviewed" 09/01/2005 - "Randomized, double-blind, controlled data on the psychotropic efficacy of antiepileptic drugs are limited mainly to bipolar disorder." 01/01/2005 - "We review the evidence on the efficacy of a spectrum of antiepileptic drugs (AED) in bipolar disorder" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 11/01/2008 - "OBJECTIVE: Psychotherapy has long been recommended as adjunctive to pharmacotherapy for bipolar disorder, but it is unclear which interventions are effective for which patients, over what intervals, and for what domains of outcome" 12/01/2005 - "Although pharmacotherapy is the mainstay of treatment strategies for bipolar disorder, research over the last 5 years suggests that combining psychologic interventions with drug treatment increases overall effectiveness, mostly by further protecting from relapse or recurrence" 01/01/1996 - "The psychosocial treatment of bipolar disorder has the potential to augment the efficacy of outpatient pharmacotherapy if it succeeds in enhancing the protective effects of the social and familial environment and the patient's adherence to drug regimes" 02/01/2003 - "BACKGROUND: Several studies have established the efficacy of psychosocial interventions as adjuncts to pharmacotherapy in the symptom maintenance of bipolar disorder" 01/01/2007 - "What is the evidence that psychosocial treatment adds to the efficacy of pharmacotherapy in forestalling episodes of bipolar disorder (BPD)" Order ALL the reference details at left...
2.	Therapeutics 08/01/2008 - "OBJECTIVE: The therapeutics for bipolar disorders are still far from adequate, and new options with improved effectiveness, safety, and tolerability in a wide range of patients are necessary" 01/01/2003 - "These new models hold much promise in delineating the underlying pathophysiology of bipolar disorder and for the development of novel, improved therapeutics" 01/01/2002 - "Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics." 08/01/2008 - "The present results strongly support the involvement of the purinergic system in the pathophysiology and therapeutics of bipolar disorder" 05/01/2008 - "Creating novel therapeutics for bipolar disorder is urgently needed" Order ALL the reference details at left...
3.	Aftercare (After-Treatment) 01/01/2002 - "This study assessed whether therapist adherence to the family focused treatment model for patients with bipolar disorder and their relatives was associated with patient outcomes at one year after treatment entry" 04/01/2007 - "Employee costs before and after treatment initiation for bipolar disorder." 05/01/2004 - "Symptom severity and functioning were evaluated before and after treatment using the severity scales of the Clinical Global Impression Scales for Bipolar Disorder (CGI-BP) and the Children's Global Assessment Scale (CGAS) respectively" 08/01/1999 - "Improvements in mania after treatment were closely correlated with decreases in ED50 (r = .76; p < .01)" 07/01/1994 - "Insight (ITAQ total score) improved significantly after treatment in both mania and schizophrenia" Order ALL the reference details at left...
4.	Phototherapy (Light Therapy) 01/01/2008 - "Dark Therapy", in which complete darkness is used as a mood stabilizer in bipolar disorder, roughly the converse of light therapy for depression, has support in several preliminary studies" 12/01/2007 - "OBJECTIVES: To perform a dose-ranging safety and efficacy study of bright light therapy for depression in women with bipolar disorder (BD)" 12/01/2007 - "Light therapy for bipolar disorder: a case series in women." 02/01/2001 - "CONCLUSIONS: Natural sunlight can be an underestimated and uncontrolled light therapy for bipolar depression" 05/01/1995 - "Seven adolescents or young adults (aged 16 to 22 years) who met DSM-III-R criteria for bipolar disorder were treated for persistent depressive symptoms (greater than three weeks) with adjunctive light therapy (10,000 lux given twice per day)" Order ALL the reference details at left...
5.	Deep Brain Stimulation 08/01/2006 - "Mania following subthalamic nucleus (STN) deep brain stimulation (DBS) is well described and obvious to both the patient and their physician" 11/12/2002 - "Mania following deep brain stimulation for Parkinson's disease." 07/10/2004 - "Three years after the implantation of electrodes in the subthalamic nucleus (STN) and the start of deep brain stimulation (DBS) for advanced Parkinson's disease, a 62-year-old man was admitted because of a stimulation-related manic state that did not respond to treatment with a mood stabiliser and that led to chaotic behaviour, megalomania, serious financial debts and mental incompetence" 07/01/2000 - "Efficacy of unilateral deep brain stimulation of the thalamic ventralis intermedius nucleus in a patient with bipolar disorder associated with Klinefelter syndrome and essential tremor" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Bipolar Disorder

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 729 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>